Skip to Content
MilliporeSigma
All Photos(1)

Documents

1269447

USP

Fenofibrate

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid isopropyl ester

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C20H21ClO4
CAS Number:
49562-28-9
Molecular Weight:
360.83
MDL number:
MFCD00133314
UNSPSC Code:
41116107
PubChem Substance ID:
329749836
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

fenofibrate

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2

InChI

1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3

InChI key

YMTINGFKWWXKFG-UHFFFAOYSA-N

Gene Information

human ... PPARA(5465)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fenofibrate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

F0048005

Fenofibrate impurity A, European Pharmacopoeia (EP) Reference Standard

1269607

Fenofibrate Related Compound A, United States Pharmacopeia (USP) Reference Standard

F0048010

Fenofibrate impurity B, European Pharmacopoeia (EP) Reference Standard

1269629

Fenofibrate Related Compound C, United States Pharmacopeia (USP) Reference Standard

1269618

Fenofibrate Related Compound B, United States Pharmacopeia (USP) Reference Standard

F0048035

Fenofibrate impurity G, European Pharmacopoeia (EP) Reference Standard

1133558

Choline Fenofibrate, United States Pharmacopeia (USP) Reference Standard

PHR2864

Fenofibrate Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

hcodes

H412

Hazard Classifications

Aquatic Chronic 3

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 2

1 of 2

Fenofibric acid analytical standard

Supelco

90568

Fenofibric acid

Bezafibrate ≥98%, solid

Sigma-Aldrich

B7273

Bezafibrate

Pitchai Balakumar et al.
Pharmacological research, 63(1), 8-12 (2010-11-26)
Fenofibrate is a third-generation fibric acid derivative employed clinically as a hypolipidemic agent to lessen the risk caused by atherosclerosis. Dyslipidemia is a condition associated with elevated levels of low-density lipoproteins (LDL), very low-density lipoproteins (VLDL) and triglycerides, and reduced
Itoro E Elijah et al.
Burns : journal of the International Society for Burn Injuries, 38(4), 481-486 (2012-01-10)
Fenofibrate is a peroxisome proliferator activated receptor alpha agonist that contains both pro and anti-inflammatory properties, and has been used in the treatment of dyslipidemia and diabetes for decades. Its receptors are expressed in the liver, skeletal muscle, cardiac, enteric
Pascale Massin et al.
Ophthalmic epidemiology, 21(5), 307-317 (2014-08-19)
Fenofibrate reduced progression of diabetic retinopathy in two large randomized studies. The effect of 135 mg fenofibric acid on diabetic macular edema (DME) was evaluated in subjects with existing DME. In this double-blind, randomized, placebo-controlled study, 110 subjects with DME not
Kate McKeage et al.
Drugs, 71(14), 1917-1946 (2011-09-29)
Fenofibrate is a fibric acid derivative indicated for the treatment of severe hypertriglyceridaemia and mixed dyslipidaemia in patients who have not responded to nonpharmacological therapies. The lipid-modifying effects of fenofibrate are mediated by the activation of peroxisome proliferator-activated receptor-α. Fenofibrate
Samuel Rommelaere et al.
PloS one, 9(8), e104925-e104925 (2014-08-21)
Liver is a major regulator of lipid metabolism and adaptation to fasting, a process involving PPARalpha activation. We recently showed that the Vnn1 gene is a PPARalpha target gene in liver and that release of the Vanin-1 pantetheinase in serum
View All Related Papers

Articles

HPLC Analysis of Fenofibrate and Its Impurities by Following the USP43-NF38 Guidelines Using a Purospher® STAR RP18e Column

An application note concerning the HPLC analysis of fenofibrate and its impurities by following the USP43-NF38 Guidelines using a Purospher® STAR RP18e Column.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service